January 14, 2021 -- Biomarker discovery company Nucleai will work with Swiss pharmaceutical developer Debiopharm to optimize development of a clinical oncology asset per a new research collaboration.
Developed with pathology datasets and machine-learning methods, the Nucleai platform may be used to help identify biomarkers for response.
The biomarkers allow further stratification of patient populations between responders and nonresponders, improve the success rate of clinical trials, and shorten time-to-market for pharmaceutical treatments, the companies said in a statement.
The research agreement includes an undisclosed upfront payment to Nucleai and milestone payments related to progress in clinical studies and development of companion diagnostics.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
